Contrasting TherapeuticsMD (TXMD) and Its Peers

TherapeuticsMD (NASDAQ:TXMD) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare TherapeuticsMD to related businesses based on the strength of its risk, dividends, earnings, profitability, analyst recommendations, valuation and institutional ownership.

Volatility & Risk

TherapeuticsMD has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, TherapeuticsMD’s competitors have a beta of -4.10, suggesting that their average share price is 510% less volatile than the S&P 500.

Profitability

This table compares TherapeuticsMD and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
TherapeuticsMD Competitors	-2,381.29%	-218.58%	-15.77%

Insider & Institutional Ownership

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares TherapeuticsMD and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TherapeuticsMD	$3.02 million	-$570,000.00	85.50
TherapeuticsMD Competitors	$5.31 billion	$3.20 billion	549.43

TherapeuticsMD’s competitors have higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings for TherapeuticsMD and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	0	0	1.00
TherapeuticsMD Competitors	7782	13868	25755	1034	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 28.99%. Given TherapeuticsMD’s competitors stronger consensus rating and higher possible upside, analysts clearly believe TherapeuticsMD has less favorable growth aspects than its competitors.

Summary

TherapeuticsMD competitors beat TherapeuticsMD on 9 of the 13 factors compared.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.